Skip to main content
. 2023 Sep 30;31(1):433–451. doi: 10.1245/s10434-023-14352-z

Table 4.

Effect of immune markers on pathologic response in the total area, tumor sample, and tumor microenvironment of surgical specimens (no 18F-FDG-PET/CT)

Post-CRT author Assessment Cut-off value Sample size n pGR (TRG1–2) n pPR (TRG3–5) Correlation biomarkers with PR in surgical specimens p-Value total area p-Value tumor p-Value TME
CD8
Fassan et al., 201944 a,b Cell count/5 HPF Median 88 23 65 pGR had significant enrichment of CD8+ compared with pPR <0.001 NA NA
Goedegebuure et al., 202124 a Cell count/mm2 Median 40 12 (TRG1) 28 (TRG2–5) TRG1 was significantly more present in a CD8-dominant infiltrate 0.027 NA NA
Haddad et al., 202246 c % ± SD Mean 17 11 6 Significant enrichment of CD8+ in pGR compared with pPR NA <0.001 0.001
Koemans et al., 202130 c Cell count/mm2 4 hotspots of 0.5 mm*0.5mm2 123 62 61 pGR had significantly less CD8+ compared with pPR 0.001 NA NA
Kotsafti et al., 202126 a,b Cell count/5 HPF Median 123 20 103 Peritumoral healthy mucosa in pGR had significant high CD8+ compared with pPR 0.05 NA NA
Soeratram et al., 202127 a Cells/mm2 Mean and median 89 55 (TRG1–3) 25 (TRG4–5) Higher CD8 in the tumor epithelium was associated with pPR; higher CD8 in tumor stroma was associated with pGR NA 0.000 0.000
CD4
Fassan et al., 202244 a,b Cell count/5 HPF Median 88 23 65 pGR had significant enrichment of CD4+ compared with pPR 0.006 NA NA
Haddad et al., 202246 c % ± SD Mean 28 13 15 pGR had significant enrichment of CD4+ compared with pPR NA 0.009 0.004
Koemans et al., 202130 c Cell count/mm2 4 hotspots of 0.5 mm*0.5mm2 123 62 61 pGR had significantly less CD4+ compared with pPR <0.001 NA NA
CD3
Haddad et al., 202246 c % ± SD Mean 88 13 15 pGR had significant enrichment of CD3+ compared with pPR NA <0.001 <0.001
Koemans et al., 202130 c Cell count/mm2 4 hotspots of 0.5 mm*0.5mm2 123 62 61 pGR had significant less CD3+ compared with pPR <0.001 NA NA
CD80
Fassan et al., 202244 a,b Cell count/5 HPF Median 88 23 65 No difference between pGR and pPR 0.4874 NA NA
Kotsafti et al., 202126 a,b Cell count/5 HPF Median 123 20 103 No difference between pGR and pPR 0.89 NA NA
PD-1
Kotsafti et al., 202126 a,b NA 123 20 103 pGR had significantly lower mRNA PD-1 compared with pPR 0.0065 NA NA
PD-L1
Fassan et al., 201944 a,b Cell count/5 HPF 88 23 65 pGR had significant levels of PD-L1 expressions either on tumor cells or in lymphocytes than pPR NA 0.004 NA
Huang et al., 201925 d >1% = positive, <1 = negative 107 28 79 Positive tumoral PD-L1 expression was significantly associated with pPR NA 0.036 NA
Koemans et al., 202130 c 0%, 1–5%, 6–9%, 10–29%, >30% 123 62 61 No association between PD-L1 positivity in tumor cells and PR; pPR had significantly more PD-L1-positive lymphocytes NA 1.00 0.001
Kotsafti et al., 202126 a,b NA 123 20 103 pGR had significantly lower mRNA PD-L1 compared with pPR 0.0005 NA NA
Soeratram et al., 202127 a <1–4%, 5–24%, 25–100% Mean and median 89 55 (TRG1–3) 25 (TRG4–5) CPS > 1 was associated with pPR 0.010 NA NA

Bold values indicate the significant values (p < 0.05)

a Pearson’s Chi-square test

b Two-tailed z-test

c Mann–Whitney U-test

d Logistic regression

18F-FDG-PET/CT F-18 fluorodeoxyglucose positron emission tomography/computed tomography, TRG tumor regression grade, pGR pathologic good responders, pPR pathologic poor responders, PR pathologic response, CRT chemoradiotherapy, CPS combined positive score, TME tumor microenvironment, NA not available, PD-1 programmed death-1, PD-L1 programmed death-ligand 1, HPF high power field, SD standard deviation